AGuIX clinical trials
How each study uses AGuIX is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the AGuIX studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
6 studies that test it; most in 2016 (1)
| Year | Studies |
|---|---|
| 2016 | 1 |
| 2018 | 1 |
| 2019 | 1 |
| 2020 | 1 |
| 2021 | 1 |
| 2022 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 0 · Other 6
University Hospital, Grenoble (2) · Centre Jean Perrin (1) · Gustave Roussy, Cancer Campus, Grand Paris (1) · Dana-Farber Cancer Institute (1) · Centre Leon Berard (1)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 1
Studies that test AGuIX.
- Nov 2026AGuIX Nanoparticles With Radiotherapy Plus Concomitant Temozolomide in the Treatment of Newly Diagnosed GlioblastomaPhase 1/2 · Centre Jean Perrin
Studies
Open first, then newest update. How each study uses AGuIX is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 6
- Nano-SMART: Nanoparticles With MR Guided SBRT in Centrally Located Lung Tumors and Pancreatic CancerRecruitingPhase 1/2Dana-Farber Cancer InstituteNCT04789486Written as AGuIXHow we know
- AGuIX Gadolinium-based Nanoparticles in Combination With Chemoradiation and BrachytherapyCompletedPhase 1Gustave Roussy, Cancer Campus, Grand ParisNCT03308604Written as Polysiloxane Gd-Chelates based nanoparticles (AGuIX)How we know
- AGuIX Nanoparticles With Radiotherapy Plus Concomitant Temozolomide in the Treatment of Newly Diagnosed GlioblastomaActive, not recruitingPhase 1/2Centre Jean PerrinNCT04881032Written as Polysiloxane Gd-Chelates based nanoparticles (AGuIX)How we know
- Radiotherapy of Multiple Brain Metastases Using AGuIX®CompletedPhase 2University Hospital, GrenobleNCT03818386Written as AGuIX®How we know
- Evaluating AGuIX® Nanoparticles in Combination With Stereotactic Radiation for Brain MetastasesTerminatedPhase 2Centre Leon BerardNCT04094077Written as AGuIXHow we know
- Radiosensitization of Multiple Brain Metastases Using AGuIX Gadolinium Based NanoparticlesCompletedPhase 1University Hospital, GrenobleNCT02820454Written as AGuIXHow we know
Codes
What other systems call AGuIX · ClinicalTrials.gg INT001579
- MeSH (NLM) C000714949AGuIXOne source ClinicalTrials.gov
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000714949 | AGuIX | One source ClinicalTrials.gov |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.